-

$undefined

N/A

(N/A)

Agios Pharmaceuticals Inc. NASDAQ:AGIO Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development.

Location: 88 Sidney St, Massachusetts, 02139-4137, US | Website: www.agios.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.414B

Cash

1.005B

Avg Qtr Burn

-82.29M

Short % of Float

9.01%

Insider Ownership

1.51%

Institutional Own.

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Sickle cell disease, Anemia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tibsovo (Ivosidenib) (IDH1m inhibitor) Details AML (Acute Myeloid Leukemia)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VORANIGO (Vorasidenib) Details Glioma, Brain tumor	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Sickle cell disease, Anemia	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Pyruvate Kinase Deficiency	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Beta thalessemia	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AG-946 Details Myelodysplastic syndrome	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AG-181 Details Phenylketonuria	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tebapivat Details Sickle cell disease, Blood disorder	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.